NuCana (NCNA) Change in Receivables (2017 - 2025)
NuCana (NCNA) reported Change in Receivables of $2.8 million for Q4 2025, up 832.28% on a YoY basis from $304189.9 in Q4 2024, and up 210.04% sequentially from -$2.6 million in Q3 2025.
NuCana (NCNA) Change in Receivables (2017 - 2025) Analysis & Trends
NuCana (NCNA) has 9 years of Change in Receivables data on file, last reported at $2.8 million in Q4 2025.
- For the quarter ending Q4 2025, Change in Receivables rose 832.28% year-over-year to $2.8 million; the trailing twelve-month figure through Dec 2025 stood at $1.7 million (up 25.47% YoY), and the FY2025 full-year result was $143717.6, down 93.53% from the prior year.
- Change in Receivables advanced to $2.8 million in Q4 2025, from -$2.6 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $2.8 million in Q4 2025 to a low of -$2.6 million in Q3 2025.
- A 5-year average of $353468.8 and a median of $413752.9 in 2022 frame the typical range for Change in Receivables.
- Across the five-year window, Change in Receivables surged 1931.52% in 2023 and slumped 326.7% in 2025, its largest moves.
- Tracing NCNA's Change in Receivables over 5 years: stood at $859602.9 in 2021, then sank by 113.92% to -$119634.8 in 2022, then jumped by 829.33% to $872529.8 in 2023, then sank by 65.14% to $304189.9 in 2024, then surged by 832.28% to $2.8 million in 2025.
- Business Quant data shows NCNA's Change in Receivables at $2.8 million in Q4 2025, -$2.6 million in Q3 2025, and $304189.9 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 75.30 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.84 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 110.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.84 Mn |
| Dec 31, 2025 | 2.84 Mn |
| Sep 30, 2025 | -2.58 Mn |
| Sep 30, 2025 | -2.58 Mn |
| Dec 31, 2024 | 304,189.94 |
| Dec 31, 2024 | 304,189.94 |
| Sep 30, 2024 | 1.14 Mn |
| Sep 30, 2024 | 1.14 Mn |
| Dec 31, 2023 | 872,529.78 |
| Dec 31, 2023 | 872,529.78 |
| Sep 30, 2023 | -958,880.39 |
| Sep 30, 2023 | -958,880.39 |
| Jun 30, 2023 | 2.19 Mn |
| Jun 30, 2023 | 2.19 Mn |
| Mar 31, 2023 | -562,780.91 |
| Mar 31, 2023 | -562,780.91 |
| Jun 30, 2022 | -119,634.85 |
| Jun 30, 2022 | -119,634.85 |
| Mar 31, 2022 | 523,315.92 |
| Mar 31, 2022 | 523,315.92 |